-
Akari Therapeutics outlines 2025 progress in shareholder letter
-
Akari Therapeutics reports preclinical data for pancreatic cancer drug
-
Akari Therapeutcis (AKTX) files for 6.375M share ADSs offering by selling stockholders
-
Akari Therapeutics reports preclinical data on novel ADC payload
-
Akari Therapeutics launches CEO Corner communication platform
-
Akari Therapeutics files two patents for cancer drug platform
-
Akari Therapeutics reports preclinical data on prostate cancer payload
-
AKARI Therapeutics files patent for cancer ADC platform
-
H.C. Wainwright Reiterates Buy Rating on Akari Therapeutics (AKTX)
-
Akari Therapeutics advances research on cancer drug payload PH1
-
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
-
Maxim Group Starts Akari Therapeutics (AKTX) at Buy
-
Akari Therapeutcis (AKTX) Granted Patent Protection Across India
-
Akari Therapeutcis (AKTX) Reports In-Line Q1 EPS
-
Akari Therapeutcis (AKTX) Appoints Mark F. Kubik as Head of Business Development - Oncology
-
Akari Therapeutcis (AKTX) Appoints Abizer Gaslightwala as CEO and President
-
Akari Therapeutcis (AKTX) Announces $7.6M Private Placement
-
Akari Therapeutics (AKTX) Announces Key Leadership Appointments
-
Akari Therapeutcis (AKTX) Appoints Torsten Hombeck as CFO
-
Akari Therapeutcis (AKTX) Regains Nasdaq Compliance
-
Akari Therapeutcis (AKTX) Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
-
Akari Therapeutcis (AKTX): Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics

